Cite
HARVARD Citation
Dimopoulos, M. et al. (2020). Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 396 (10245), pp. 186-197. [Online].